ストックスクリーナーアプリを入手
137.16
0.36%
-0.175
前日終値:
$137.34
開ける：
$136.8
24時間の取引高:
123.85K
Relative Volume:
0.02
時価総額：
$170.15B
収益：
$29.45B
当期純損益:
$8.51B
株価収益率:
20.22
EPS:
6.7823
ネットキャッシュフロー:
$9.46B
1週間 パフォーマンス:
-5.23%
1か月 パフォーマンス:
-7.31%
6か月 パフォーマンス:
+20.39%
1年 パフォーマンス:
+28.21%
1日の値動き範囲:
$136.68
$137.28
1週間の範囲:
$136.44
$143.79
52週間の値動き範囲:
$93.37
$157.29
Gilead Sciences Inc Stock (GILD) Company Profile
Compare GILD vs LLY, JNJ, ABBV, AZN, MRK
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
GILD
Gilead Sciences Inc
|
137.06 | 170.50B | 29.45B | 8.51B | 9.46B | 6.7823 |
LLY
Lilly Eli Co
|
906.12 | 813.11B | 65.18B | 20.64B | 5.96B | 22.59 |
JNJ
Johnson Johnson
|
233.43 | 567.04B | 94.19B | 26.80B | 19.70B | 11.05 |
ABBV
Abbvie Inc
|
202.58 | 362.35B | 61.16B | 4.19B | 17.82B | 2.3614 |
AZN
Astrazeneca Plc
|
183.09 | 285.46B | 58.80B | 10.24B | 8.98B | 3.2788 |
MRK
Merck Co Inc
|
114.83 | 286.01B | 64.93B | 18.26B | 12.36B | 7.2751 |
Gilead Sciences Inc Stock (GILD) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-03-10 | 開始されました | Jefferies | Buy |
| 2026-02-20 | 開始されました | Barclays | Equal Weight |
| 2026-02-11 | 繰り返されました | Needham | Buy |
| 2026-01-07 | 再開されました | UBS | Buy |
| 2025-11-24 | 再開されました | Truist | Buy |
| 2025-11-13 | 開始されました | Scotiabank | Sector Outperform |
| 2025-08-19 | アップグレード | Daiwa Securities | Neutral → Outperform |
| 2025-08-08 | アップグレード | Truist | Hold → Buy |
| 2025-07-25 | アップグレード | Needham | Hold → Buy |
| 2025-04-22 | 再開されました | Cantor Fitzgerald | Overweight |
| 2025-03-04 | 繰り返されました | Oppenheimer | Outperform |
| 2025-02-18 | アップグレード | Deutsche Bank | Hold → Buy |
| 2025-02-13 | アップグレード | DZ Bank | Hold → Buy |
| 2025-01-10 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2024-12-10 | 再開されました | BofA Securities | Buy |
| 2024-11-15 | 開始されました | Wolfe Research | Outperform |
| 2024-11-14 | 開始されました | Citigroup | Buy |
| 2024-11-08 | ダウングレード | Maxim Group | Buy → Hold |
| 2024-10-21 | アップグレード | Leerink Partners | Market Perform → Outperform |
| 2024-10-17 | 開始されました | Bernstein | Outperform |
| 2024-10-07 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2024-07-08 | アップグレード | Raymond James | Mkt Perform → Outperform |
| 2024-05-01 | 繰り返されました | Maxim Group | Buy |
| 2024-04-24 | アップグレード | HSBC Securities | Reduce → Hold |
| 2024-02-22 | ダウングレード | Truist | Buy → Hold |
| 2023-11-09 | 開始されました | Deutsche Bank | Hold |
| 2023-09-08 | アップグレード | BofA Securities | Neutral → Buy |
| 2023-09-06 | 開始されました | HSBC Securities | Reduce |
| 2023-07-24 | 繰り返されました | Barclays | Equal Weight |
| 2023-05-16 | アップグレード | BMO Capital Markets | Market Perform → Outperform |
| 2023-04-28 | 再開されました | Piper Sandler | Overweight |
| 2023-01-03 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-12-13 | 再開されました | BofA Securities | Neutral |
| 2022-12-09 | ダウングレード | DZ Bank | Buy → Hold |
| 2022-10-31 | アップグレード | Barclays | Underweight → Equal Weight |
| 2022-10-28 | 繰り返されました | BMO Capital Markets | Market Perform |
| 2022-10-28 | 繰り返されました | Cowen | Outperform |
| 2022-10-28 | 繰り返されました | JP Morgan | Overweight |
| 2022-10-28 | 繰り返されました | Jefferies | Buy |
| 2022-10-28 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2022-10-28 | 繰り返されました | RBC Capital Mkts | Outperform |
| 2022-10-28 | アップグレード | Truist | Hold → Buy |
| 2022-10-28 | 繰り返されました | Wells Fargo | Equal Weight |
| 2022-10-04 | アップグレード | JP Morgan | Neutral → Overweight |
| 2022-07-13 | 開始されました | Cantor Fitzgerald | Neutral |
| 2022-05-23 | 開始されました | SVB Leerink | Mkt Perform |
| 2022-02-28 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
| 2022-02-02 | 繰り返されました | BMO Capital Markets | Outperform |
| 2022-02-02 | 繰り返されました | BofA Securities | Neutral |
| 2022-02-02 | 繰り返されました | RBC Capital Mkts | Outperform |
| 2022-02-02 | 繰り返されました | Truist | Hold |
| 2022-02-02 | 繰り返されました | Wells Fargo | Equal Weight |
| 2022-01-28 | アップグレード | Argus | Hold → Buy |
| 2022-01-06 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2021-12-09 | 再開されました | Wells Fargo | Equal Weight |
| 2021-12-06 | 開始されました | Goldman | Neutral |
| 2021-11-19 | アップグレード | BMO Capital Markets | Market Perform → Outperform |
| 2021-11-19 | 再開されました | Piper Sandler | Neutral |
| 2021-10-20 | 再開されました | Cowen | Outperform |
| 2021-07-30 | 繰り返されました | BMO Capital Markets | Market Perform |
| 2021-07-30 | 繰り返されました | RBC Capital Mkts | Outperform |
| 2021-04-01 | アップグレード | Bernstein | Mkt Perform → Outperform |
| 2021-03-30 | アップグレード | Redburn | Neutral → Buy |
| 2021-01-19 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2021-01-04 | アップグレード | Guggenheim | Neutral → Buy |
| 2020-11-03 | 再開されました | Morgan Stanley | Equal-Weight |
| 2020-10-28 | 開始されました | UBS | Neutral |
| 2020-09-30 | 再開されました | Jefferies | Buy |
| 2020-09-15 | アップグレード | Maxim Group | Hold → Buy |
| 2020-07-31 | 繰り返されました | Credit Suisse | Neutral |
| 2020-07-31 | 繰り返されました | Morgan Stanley | Equal-Weight |
| 2020-07-31 | 繰り返されました | Piper Sandler | Overweight |
| 2020-07-31 | 繰り返されました | RBC Capital Mkts | Outperform |
| 2020-07-31 | 繰り返されました | SunTrust | Hold |
| 2020-07-31 | 繰り返されました | Wells Fargo | Equal Weight |
| 2020-07-20 | アップグレード | Credit Suisse | Underperform → Neutral |
| 2020-06-03 | アップグレード | SVB Leerink | Mkt Perform → Outperform |
| 2020-05-26 | アップグレード | SunTrust | Sell → Hold |
| 2020-05-01 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2020-05-01 | ダウングレード | Raymond James | Outperform → Mkt Perform |
| 2020-05-01 | ダウングレード | SunTrust | Hold → Sell |
| 2020-04-27 | ダウングレード | UBS | Buy → Neutral |
| 2020-04-20 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
| 2020-04-20 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2020-04-17 | ダウングレード | CFRA | Hold → Sell |
すべてを表示
Gilead Sciences Inc (GILD) 最新ニュース
Bernstein reiterates Gilead stock rating on Ouro acquisition - Investing.com
Scotiabank Maintains Gilead Sciences(GILD.US) With Buy Rating, Maintains Target Price $177 - Moomoo
Gilead Chief Gets 20% Pay Bump, Still Falls Short of $30M Club - BioSpace
Gilead Drops $2.1B for Ouro, Hopes To Split Cost with Galapagos - BioSpace
Gilead to Buy Ouro Medicines for $2.2 Billion. ‘Immune Reset’ Is Key to Future Gains. - Barron's
Goldman Sachs reiterates Neutral on Gilead stock after Ouro deal - Investing.com
Gilead to Acquire Ouro Medicines in Over $2 Billion Deal - eHealth Magazine
This pharma company’s twice-yearly shot is putting the end of HIV/AIDS within reach - Fast Company
E. Ohman J or Asset Management AB Increases Stock Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead's $2.2B Ouro buyout delivers autoimmune T-cell engager, new purpose for Galapagos - Fierce Biotech
Gilead Sciences (GILD) Acquires Ouro Medicines for $1.675 Billio - GuruFocus
Gilead nearing $2B takeout of Ouro: report - FirstWord Pharma
Gilead Sciences to buy Ouro Medicines to boost T cell therapy for autoimmune diseases (GILD:NASDAQ) - Seeking Alpha
M&A News: Gilead Bets $2B+ on Ouro Medicines to Power Immunology Growth - TipRanks
Keymed Biosciences shares rise on $320 mln windfall from Gilead-Ouro deal - Investing.com
Gilead Reportedly Eyes Yet Another Acquisition Worth $2B After Arcellx Deal - Stocktwits
Gilead snags another local company, this one launched little more than a year ago - The Business Journals
Gilead boosts immunology pipeline with over $2 billion buyout of Ouro Medicines - KELO-AM
Gilead Sciences to Buy Ouro Medicines, Collaborate With Galapagos on Purchased Assets - WSJ
Gilead nears up to $2 billion buyout of biotech Ouro Medicines, FT reports By Reuters - Investing.com
Gilead (GILD) Expands Portfolio with Acquisition of Ouro Medicines - GuruFocus
Gilead to buy biotech firm Ouro Medicines in over $2 billion deal By Reuters - Investing.com
Gilead to buy biotech firm Ouro Medicines in over $2 billion deal - AOL.com
Gilead to buy Ouro Medicines for up to $2.2 billion By Investing.com - Investing.com India
Galapagos and Gilead in Advanced Discussions to Collaborate on Advancing First in Class T Cell Engager Program for Autoimmune Diseases - The Manila Times
Gilead Sciences to acquire Ouro Medicines in push for autoimmune disease therapies - Traders Union
Gilead to buy Ouro Medicines for up to $2.2 billion - Investing.com
Gilead to acquire Ouro Medicines for up to $2.18 billion By Investing.com - Investing.com India
Galapagos and Gilead in Advanced Discussions to Collaborate on Advancing First in Class T Cell Engager Program for Autoimmune Diseases - GlobeNewswire Inc.
Gilead Sciences To Acquire Ouro Medicines To Advance First In Class T Cell Engager Program For Autoimmune Diseases - TradingView
Gilead to Buy Ouro Medicines for Its Autoimmune Drugs - Bloomberg.com
Gilead Sciences to Acquire Ouro Medicines to Advance First in Class T Cell Engager Program for Autoimmune Diseases - Business Wire
Gilead Sciences (GILD) Nears $2 Billion Acquisition of Ouro Medi - GuruFocus
Gilead (GILD) Edges Toward $2 Billion Acquisition of Ouro Medici - GuruFocus
Gilead nearing up to $2 billion buyout of biotech Ouro Medicines, FT reports - Yahoo Finance
Gilead Sciences nears $2 billion Ouro Medicines acquisition - Investing.com South Africa
Gilead nears up to $2 billion buyout of biotech Ouro Medicines, FT reports - marketscreener.com
Gilead nears up to $2bn deal for autoimmune biotech Ouro Medicines - Financial Times
Gilead boss' compensation jumped 20% last year to $28.4 million - The Business Journals
Weekly Recap: Should I set a stop loss on Gilead Sciences Inc2026 WrapUp & Verified Entry Point Signals - baoquankhu1.vn
Gilead Sciences to Buy Arcellx in $7.8B Deal to Strengthen Cell Therapy Portfolio - The Healthcare Technology Report.
Stock Recap: What is the next catalyst for Gilead Sciences Inc2026 Trade Ideas & Weekly Consistent Profit Watchlists - baoquankhu1.vn
GILD.SW Gilead Sciences SIX up 70.33% pre-market 23 Mar 2026: valuation risk - Meyka
Arcellx earnings on deck ahead of Gilead acquisition close - Investing.com
Nordea Investment Management AB Increases Position in Gilead Sciences, Inc. $GILD - MarketBeat
New England Research & Management Inc. Buys New Stake in Gilead Sciences, Inc. $GILD - MarketBeat
IAM Advisory LLC Takes $1.27 Million Position in Gilead Sciences, Inc. $GILD - MarketBeat
BCGM Wealth Management LLC Invests in Gilead Sciences - National Today
BCGM Wealth Management LLC Makes New Investment in Gilead Sciences, Inc. $GILD - MarketBeat
Here is what to know beyond why Gilead Sciences, Inc. (GILD) is a trending stock - MSN
Former Gilead Sciences GC To Earn Over $2.5M Severance - Law360
Gilead Sciences Inc (GILD) 財務データ
収益
当期純利益
現金流量
EPS
Gilead Sciences Inc (GILD) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Dickinson Andrew D | Chief Financial Officer |
Mar 16 '26 |
Sale |
144.23 |
3,000 |
432,690 |
179,191 |
0.24%
大文字化:
|
ボリューム (24 時間):